Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)
To determine the safety and tolerability of galunisertib when combined with Stereotactic Body Radiotherapy (SBRT) (hypofractionated radiation).
ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
DRUG: Galunisertib 150mg by mouth twice a day|RADIATION: Stereotactic Body Radiotherapy (SBRT)
Safety based upon standard laboratory and clinical adverse event monitoring, Number of participants with treatment-related adverse events as assessed by CTCAE v4, Cycle 1 Day 15 through date of progression assessed up to 90 months
Progression free survival (PFS) who are receiving the combination of galunisertib plus SBRT as compared to the PFS of Galunisertib alone in historical controls., From Cycle 1 Day 1 to progression of disease, Cycle 1 Day 15 through date of progression assessed up to 90 months|Response rate, by conventional CT and MRI, Cycle 3 Day 1 and every 8 weeks thereafter up to 90 months|Overall survival (OS), start of treatment to death due to any cause or last patient contact alive, Cycle 1 Day 1 to death due to any cause or last patient contact alive up to 90 months|Inhibition of TGF-Î² signaling by intervention as evidenced by downstream changes in this pathway, Cycle 1 Day 15 through date of progression assessed up to 90 months|Promotion of anti-tumor immunity with addition of intervention to SBRT, Cycle 1 Day 15 through date of progression assessed up to 90 months
To determine the safety and tolerability of galunisertib when combined with Stereotactic Body Radiotherapy (SBRT) (hypofractionated radiation).